본문으로 건너뛰기
← 뒤로

Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in or .

1/5 보강
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 📖 저널 OA 33% 2022: 4/6 OA 2024: 4/10 OA 2025: 30/61 OA 2026: 34/143 OA 2022~2026 2026 Vol.44(10) p. 883-892
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
960 participants with ovarian cancer were identified (814 and 146 carriers).
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Risk-reducing mastectomy should not be recommended routinely, but might be considered for long-term survivors. Magnetic resonance imaging surveillance and/or mammography is a realistic alternative.

Apostol AI, Gronwald J, Cybulski C, Kim RH, Møller P, Karlan BY, Bordeleau L, Schrader I, Ramón Y Cajal T, Pal T, Eisen A, Singer CF, Couch FJ, Zakalik D, Metcalfe K, Olopade O, Tung N, Fruscio R, Foulkes WD, Aeilts A, Sun P, Lubinski J, Narod SA, Kotsopoulos J

📝 환자 설명용 한 줄

[PURPOSE] carriers face high risks of developing both breast and ovarian/fallopian tube cancers (hereafter referred to as ).

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 0.12 to 0.27
  • 추적기간 4.9 years

이 논문을 인용하기

↓ .bib ↓ .ris
APA Apostol AI, Gronwald J, et al. (2026). Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in or .. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(10), 883-892. https://doi.org/10.1200/JCO-25-01648
MLA Apostol AI, et al.. "Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in or .." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 44, no. 10, 2026, pp. 883-892.
PMID 41762747 ↗

Abstract

[PURPOSE] carriers face high risks of developing both breast and ovarian/fallopian tube cancers (hereafter referred to as ). Among carriers with ovarian cancer, it is not clear whether the risk of breast cancer is sufficiently high that risk-reducing mastectomy should be offered. This study aimed to assess the risk of breast cancer carriers after a diagnosis of ovarian cancer.

[METHODS] We included women with a pathogenic/likely pathogenic variant in or , a diagnosis of ovarian cancer, and no other cancer history and no risk-reducing bilateral mastectomy. Women were followed for incident breast cancer from the date of ovarian cancer diagnosis or the date of baseline questionnaire, whichever came last. The 5-, 10-, and 15-year cumulative risks of breast cancer were compared for women with ovarian cancer and an age-matched set of control women without ovarian cancer.

[RESULTS] A total of 960 participants with ovarian cancer were identified (814 and 146 carriers). After a mean follow-up of 4.9 years, 41 women (4.3%) developed breast cancer, at a mean age at diagnosis of 57.5 years (range, 39-74). Actuarial cumulative breast cancer risks after ovarian cancer were 4.4%, 8.9%, and 11.5% at 5, 10, and 15 years, respectively. Only three breast cancer-related deaths occurred. Among 741 age-matched carriers ovarian cancer, actuarial cumulative risks of breast cancer were 20.9%, 38.6%, and 47.2% at 5, 10, and 15 years, respectively. The hazard ratio for breast cancer, after an ovarian cancer diagnosis, compared with no ovarian cancer, was 0.18 ([95% CI, 0.12 to 0.27]; < .0001).

[CONCLUSION] After ovarian cancer, carriers have a relatively low risk of breast cancer. Risk-reducing mastectomy should not be recommended routinely, but might be considered for long-term survivors. Magnetic resonance imaging surveillance and/or mammography is a realistic alternative.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반